Roche Blockbuster Lucentis Gets FDA Nod For Broader Use

Law360, New York (August 10, 2012, 4:04 PM EDT) -- Roche Holding AG’s blockbuster medicine Lucentis on Friday became the first pharmaceutical approved by the U.S. Food and Drug Administration for treatment of diabetic macular edema, an eye condition affecting more than half a million Americans.

The drug is marketed in the U.S. by Roche unit Genentech Inc., which says 560,000 diabetics suffer from the eye disease and that 75,000 new cases are diagnosed each year. Shipments are set to begin within days, likely boosting already strong sales of Lucentis, which racked up domestic revenues of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.